Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Munir, Talha; R. Brown, Jennifer; O’Brien, Susan; C. Barrientos, Jacqueline; M. Barr, Paul; Reddy, Nishitha; Coutré, Steven; S. Tam, Constantine; P. Mulligan, Stephen; Jaeger, Ulrich; J. Kipps, Thomas; Moreno, Carol; Montillo, Marco; A. Burger, Jan; C. Byrd, John; Hillmen, Peter; Dai, Sandra; Szőke, Anita; P. Dean, James; A. Woyach, Jennifer

doi:10.1002/ajh.25638

Public

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Published in American Journal of Hematology • Sep 12, 2019

Authors:

Talha Munir

Jennifer R. Brown

Susan O’Brien

Abstract

Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single-agent ibrutinib over of...

Subject

Ibrutinib

Chronic lymphocytic leukemia

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!